Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Hepatology International
|
March 7, 2026
Immune biomarkers predicting response to G-CSF in acute-on-chronic liver failure: results from a GRAFT trial sub-study
Katrin Splith, Nadja Berndt, Philipp K Haber, et al.
Gut
|
May 18, 2022
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
Miguel A Martin-Serrano, Benjamin Kepecs, Miguel Torres-Martin, et al.
Gut
|
February 24, 2022
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Carla Montironi, Florian Castet, Philipp K Haber, et al.
Molecular Cancer Therapeutics
|
February 13, 2023
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2022
Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
Laura Torrens, Marc Puigvehí, Miguel Torres-Martín, et al.
JHEP Reports : Innovation in Hepatology
|
April 28, 2025
Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis
Kornelius Schulze, Tim Daniel Rose, Lorenz Adlung, et al.
Gastroenterology
|
September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Philipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Journal of Hepatology
|
December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma
Sarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
Gut
|
April 28, 2022
CXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B G Mackey, Thomas Jamieson, et al.
Nature
|
March 25, 2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Hepatology International
|
March 7, 2026
Immune biomarkers predicting response to G-CSF in acute-on-chronic liver failure: results from a GRAFT trial sub-study
Katrin Splith, Nadja Berndt, Philipp K Haber, et al.
Gut
|
May 18, 2022
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
Miguel A Martin-Serrano, Benjamin Kepecs, Miguel Torres-Martin, et al.
Gut
|
February 24, 2022
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Carla Montironi, Florian Castet, Philipp K Haber, et al.
Molecular Cancer Therapeutics
|
February 13, 2023
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2022
Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
Laura Torrens, Marc Puigvehí, Miguel Torres-Martín, et al.
JHEP Reports : Innovation in Hepatology
|
April 28, 2025
Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis
Kornelius Schulze, Tim Daniel Rose, Lorenz Adlung, et al.
Gastroenterology
|
September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Philipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Journal of Hepatology
|
December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma
Sarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
Gut
|
April 28, 2022
CXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B G Mackey, Thomas Jamieson, et al.
Nature
|
March 25, 2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Page
of 5